Elon Musk unveiled a new direction for Tesla’s Optimus robot at a New York City event this week. The humanoid robot could eventually perform surgical procedures. Musk framed the initiative as a solution to the global shortage of skilled surgeons.
The announcement comes as Tesla’s stock took a hit. Shares dropped 9.18% over the past week. The decline reflects broader market trends as investors take profits from AI and tech stocks after a strong run.
On Friday, TSLA shares recovered slightly. The stock closed at $404.35, up 0.59% for the day.
Musk positioned the surgical robot concept under what he calls Master Plan Part IV. This represents a shift for Tesla from clean energy to widespread tech integration in daily life. The company wants to build tools for tasks requiring precise skills.
The current Optimus robot remains in early development. It can walk and lift light objects. The robot can pick up eggs without breaking them. These are far cries from surgical precision.
Tesla plans to unveil an upgraded Optimus model in early 2026. The next version will feature more intricate hand components. This should allow for finer, more delicate movements over time.
No healthcare-specific version exists yet. Tesla is still in preliminary stages of this medical concept. The company is also building production lines to manufacture robots at scale, targeting one million units annually once full production begins.
Medical professionals say Musk’s surgical robot vision will take considerable time to realize. Current medical robots require human operators in the room at all times. Robots must respond quickly to unexpected complications during procedures.
Regulatory hurdles present another major obstacle. Existing medical robots fall under established healthcare regulations. An autonomous surgical robot would face much stricter standards. It would need extensive testing to prove safety at every step.
The approval process would take years and require substantial evidence. Experts point out that no regulatory framework currently exists for fully autonomous robots in clinical settings. This gap makes the challenge even tougher.
Medical procedures can change rapidly and unpredictably. A surgical robot must handle these shifts safely and precisely. That’s a tall order for current technology.
Ron Baron, a billionaire investor with substantial Tesla holdings, maintains his bullish stance. He believes the market undervalues Tesla’s potential in robotics and supercomputers. Baron predicts the stock could hit $10,000 within ten years, driven by these new ventures and continued innovation.
Wall Street analysts show mixed sentiment. The consensus rating stands at Hold. The average price target sits at $382.54, suggesting a 5.39% downside from current levels.
Some analysts exercise caution given recent volatility and Musk’s compensation package. Others, like Wedbush’s Daniel Ives, remain optimistic about Tesla’s AI-driven future. Ives views Musk’s leadership as critical for navigating the company’s expansion into AI and autonomous technology.
The stock decline came during a broader tech sell-off. Investors took profits after strong gains in AI and technology sectors. Tesla’s ambitious AI projects, including Optimus and the Robotaxi service, were highlighted in a recent company meeting led by Tesla AI chief Ashok Elluswamy.
The post Tesla (TSLA) Stock: Musk Reveals Surgical Ambitions for Optimus Robot as Shares Fall appeared first on CoinCentral.
